Cargando…
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
Implementation of the Oncotype DX assay has led to a change in the manner in which chemotherapy is utilized in patients with early stage, estrogen receptor (ER)-positive, node-negative breast cancer; ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the...
Autores principales: | McVeigh, Terri P, Kerin, Michael J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459968/ https://www.ncbi.nlm.nih.gov/pubmed/28615971 http://dx.doi.org/10.2147/BCTT.S109847 |
Ejemplares similares
-
The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre
por: McVeigh, Terri Patricia, et al.
Publicado: (2014) -
Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
por: Aherne, T. M., et al.
Publicado: (2020) -
Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017) -
The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
por: Goldstein, Daniel A., et al.
Publicado: (2020) -
Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX
por: Sengupta, Aditya K., et al.
Publicado: (2020)